Research
Hormonal
Weight loss achieved through GLP-1–based antiobesity medications affects weight regain, fat-free mass, and skeletal muscle mass in people with obesity.
Practitioners should consider the impact of GLP-1 medications on body composition when managing obesity.
StrongSupportsmedium confidence
This Viewpoint explores the effects of weight loss achieved through GLP-1–based antiobesity medications on weight regain, fat-free mass, and skeletal muscle mass in people with obesity.
Why this rating
The abstract indicates a viewpoint, suggesting a synthesis of existing evidence.
Source
Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?
Caterina Conte et al. · JAMA · 2024
DOI 10.1001/jama.2024.6586
otherCited 161×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →